Tagomics

Executive Summary

Tagomics is a UK-based biotechnology company pioneering a unified multiomic platform that combines genetic, epigenetic, and fragmentomic data with advanced machine learning to discover novel disease biomarkers. By integrating these diverse molecular layers into a single workflow, the company aims to transform disease diagnosis, offering a more comprehensive and accurate approach than traditional genomic methods alone. Their technology has potential applications in early detection, disease monitoring, and therapeutic targeting across oncology, neurology, and other therapeutic areas. With a strong focus on epigenomic profiling—a rapidly advancing field—Tagomics is positioned to capitalize on the growing demand for multiomic diagnostics that can uncover disease mechanisms missed by DNA sequencing alone. Tagomics operates in the competitive diagnostics and genomics space, but its differentiated approach of combining multiple omic data types could provide a significant advantage. While the company remains private and has not disclosed funding rounds or clinical milestones, the increasing interest in epigenomic biomarkers and the push for liquid biopsy innovations create a favorable market environment. Key near-term catalysts include potential partnerships with pharmaceutical companies for biomarker discovery, validation studies in cancer or neurological indications, and a Series A fundraising round. The conviction score is moderate, reflecting the early stage and limited public information, but the technology's novelty and market tailwinds support a cautiously optimistic outlook.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Pharma Partnership for Biomarker Discovery60% success
• Q4 2026Publication of Clinical Validation Study in Oncology55% success
• Q3 2026Series A Funding Round Closing70% success